Scottish CMO makes US appointment

2 May 2016

Senior appointment made just weeks after the sterile manufacturing specialist unveiled a significant surge in demand for its services from the US, driven by biotechnology firms looking for small-scale aseptic manufacturing capabilities in the EU to support clinical trials.

Symbiosis Pharmaceutical Services has further strengthened its North American presence with the appointment of an experienced executive to support increased demand for its sterile filling services from biotech companies.

Scottish CMO makes US appointment
Caption: US BOOST: Doctor Thomas Scullion joins Symbiosis

The UK-based contract manufacturing organisation (CMO) has appointed Dr Thomas Scullion as a US business development manager to aid the company’s growing commercial interests and client relationships in the US.

The senior appointment has been made just weeks after the sterile manufacturing specialist unveiled a significant surge in demand for its services from the US, driven by biotechnology firms looking for small-scale aseptic manufacturing capabilities in the EU to support clinical trials.

Thomas joins the CMO’s commercial team having worked in business development for the world’s largest drug discovery CRO. He has spent the majority of his career working within the life science industry across both the public and private sectors.

Colin MacKay, CEO at Symbiosis Pharmaceutical Services, said: “North America continues to be the strongest area of growth for our business so it is essential that we have the best expertise and a sufficient resource in place to drive opportunities for commercial development alongside managing existing relationships in this key territory.

“Many US companies undertaking clinical trials in the EU are electing to use a GMP manufacturer who is based in that market, such as Symbiosis, to facilitate effective compliance with the QP requirements demanded for release of drug product for clinical trial use.

“Thomas has an impressive track record and we expect he will bring great energy and strategic focus to his new role. Our reputation continues to grow in the outsourcing sector as the ‘go-to’ CMO for small-scale sterile filling and our newest recruit will proactively promote and reinforce this core message in the US.”

Symbiosis specialises in the aseptic fill/finish of biologic and small molecule pharmaceutical products into vials. The CMO focuses on the sterile manufacture of injectable drug products in both liquid and lyophilized formulations.

With a PhD in neuropharmacology, Thomas will be responsible for building and maintaining relationships in the US, prospecting new opportunities and helping the company’s strategic expansion in the territory.

Thomas said: “I was initially attracted to Symbiosis due to the company’s impressive historical growth together with its strong presence and reputation in the contract manufacturing sector.

“Having met the CEO Colin and the rest of the commercial team, I was drawn by the undeniably infectious ambition of the company. As an ambitious individual, I know that opportunities to become an important influencer in such a dynamic CMO are few and far between.

“There is a real sense of togetherness in the business and I look forward to taking the company’s world class capabilities to the US and delivering even greater commercial success based on our proven competitive strengths.”

Read More

Related tags

Market News

Related news

Pharmapack Europe 2019 Award Winners

Pharmapack Europe 2019 Award Winners

7 Feb 2019

Awards showcased a wide range of industry-changing discoveries in drug delivery, packaging and automation.

Read more 
Brexit - the EU FMD's painful problem

Brexit - the EU FMD's painful problem

7 Feb 2019

Teething problems are no stranger to the implementation of new regulations, but with the EU FMD, Brexit came like a set of wisdom teeth – late, painful and problematic.

Read more 
New series of advanced freeze dryers

New series of advanced freeze dryers

6 Feb 2019

The LyoConstellation series allows the development of highly aggressive cycles and the mapping of the furthest reaches of theoretical design space for a formulation.

Read more 
Hitachi Chemical to acquire apceth Biopharma

Hitachi Chemical to acquire apceth Biopharma

5 Feb 2019

Acquisition will strengthen Hitachi's presence in the second-largest cell and gene therapy market in the world.

Read more 
FDA approves first generic Advair Diskus

FDA approves first generic Advair Diskus

4 Feb 2019

Mylan's Wixela Inhub is the first FDA-approved therapeutically equivalent generic of Advair Diskus (fluticasone propionate and salmeterol inhalation powder) for certain patients with asthma or COPD.

Read more 
Sartorius joins the community of the National Institute for Innovation in Manufacturing Biopharmaceuticals

Sartorius joins the community of the National Institute for Innovation in Manufacturing Biopharmaceuticals

3 Feb 2019

Company hopes to contribute substantially to further optimizing and accelerating the current manufacturing processes in the biopharmaceutical industry.

Read more 
Particle Sciences partners with Encube Ethicals to develop novel vaginal rings

Particle Sciences partners with Encube Ethicals to develop novel vaginal rings

31 Jan 2019

The partnership will focus on rings for the administration of existing approved drugs, improving drug effectiveness and patient compliance.

Read more 
Manufacturing consultancy up 150% as life sciences prepare for a digital future

Manufacturing consultancy up 150% as life sciences prepare for a digital future

30 Jan 2019

Increasing appetite for digitised manufacturing and using data to improve GMP manufacturing.

Read more 
SGS expands testing capabilities at its Glasgow facility

SGS expands testing capabilities at its Glasgow facility

29 Jan 2019

Clients will benefit from a fully comprehensive range of validated biosafety methods to support cell bank and viral vaccine manufacturing and lot release of drug product.

Read more 
UK and Russia sign MoU on regulatory co-operation on medicines

UK and Russia sign MoU on regulatory co-operation on medicines

29 Jan 2019

Medicines regulators of the UK and Russian set out key principles to support their collaboration on improving public health.

Read more